Center for Integrated Diagnostics, Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
Center for Integrated Diagnostics, Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA
Oncologist. 2018 Jun;23(6):647-649. doi: 10.1634/theoncologist.2017-0591. Epub 2018 Mar 9.
This Commentary addresses the FDA approval of pembrolizumab and the changes necessary in clinical practice to identify patients who would benefit from such treatment.
本述评探讨了 pembrolizumab 获得 FDA 批准的情况,以及为了确定哪些患者将从这种治疗中获益,临床实践中需要做出的改变。